Iovance (IOVA) Reports Q1 2026 Earnings with Strong Revenue Growth
Iovance Biotech reported first-quarter earnings for fiscal year 2026, showing a significant increase in revenue driven by the adoption of Amtagvi and demand for Proleukin. Total revenue reached $71 million, up approximately 45% from the prior year.
Tickers: $IOVA